COVID-19 Immunity Testing: A Passport to Inequity
By Françoise Baylis and Natalie Kofler,
Issues in Science and Technology
| 04. 29. 2020
In an already heavily stratified society, the introduction of immunity passports is ethically problematic. They would not only exacerbate current inequities but also create a novel layer of biological inequity.
As COVID-19 case numbers start to plateau in various places, some governments are now focusing on how best to ease restrictions and reopen the economy. In the absence of herd immunity for the population—for which the threshold may be as high as 82%—next steps are not obvious.
Recently, some have touted “immunity passports” for people who have survived infection with SARS-CoV-2 (the novel coronavirus that causes COVID-19) and tested positive for SARS-CoV-2 antibodies. Under this proposal, citizens deemed immune to the virus through serological testing (a type of blood test) could be freed from current restrictions and allowed to return to work. According to media reports, Chile is poised to become the first country to issue some kind of immunity cards. Others considering this option include Australia, Germany, Italy, the United Kingdom, and the United States.
In an already heavily stratified society, the introduction of immunity passports is ethically problematic. They would not only exacerbate current inequities but also create a novel layer of biological inequity—one based on a potentially ineffective measure of immunity.
Infection with...
Related Articles
By Vittoria Vardanega, SWI swissinfo.ch | 02.13.2026
In recent years, sperm donation has produced family trees of unprecedented size, stretching across countries and, in some cases, continents. Stories of “mass donors” have captured public attention, most recently through the Netflix documentary series, The Man with 1,000 Kids...
By Jonathan D. Moreno, Hastings Center Bioethics Forum | 02.09.2026
When I began to write a book about bioethics and the rules-based international order, the idea that the world was facing the greatest geopolitical change since World War II was uncontroversial for those who were paying attention to such esoterica...
By Zachary Brennan, Endpoints News | 02.23.2026
The FDA is spelling out the details of a new pathway to help speed personalized cell and gene therapies to market for rare diseases.
Monday’s long-awaited draft guidance outlines the agency’s “plausible mechanism” framework, a pathway FDA Commissioner Marty Makary...
By David Jensen, California Stem Cell Report | 02.10.2026
Touchy issues involving accusations that California’s $12 billion gene and stem cell research agency is pushing aside “good science” in favor of new priorities and preferences will be aired again in late March at a public meeting in Sacramento.
The...
